Companies Sutro Biopharma, Inc
Sutro Biopharma (STRO): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sutro Biopharma, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers7th pct.Of 17 peer CEOs
CEO pay, last three years
- $1,443,360FY2024
- $1,575,930FY2025
CEO total pay was $1,575,930 in fiscal 2025, up from $1,443,360 in fiscal 2024.
FY2025: salary $652,000 · bonus $0 · stock awards $167,400 · option awards $245,280
Executives and directors
Jane Chung · CEOWilliam Newell · CEOGregory Chow · CFOHans-Peter Gerber · Chief Scientific OfficerConnie Matsui · Independent DirectorDaniel H. Petree · Independent DirectorHeidi Hunter · Independent DirectorJames Panek · Independent DirectorJane Chung, R.Ph · DirectorJohn Freund, M.D · Former director (through FY2025)Jon Wigginton, M.D · Independent DirectorJoseph M. Lobacki · Independent DirectorMichael Dybbs, Ph.D · Independent DirectorSukhi Jagpal · Independent Director
Frequently asked questions
Who was the highest-paid executive at Sutro Biopharma, Inc in fiscal 2025?
As disclosed, William Newell (Former Chief Executive Officer) was the highest-paid executive at Sutro Biopharma, Inc in fiscal 2025, with total compensation of $1,671,311.
How does Sutro Biopharma, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Jane Chung's total compensation ranked at the 7th percentile of Sutro Biopharma, Inc's disclosed peer group.
How did shareholders vote on Sutro Biopharma, Inc's executive compensation?
As disclosed, 99.8% of shareholders supported Sutro Biopharma, Inc's executive compensation in the latest say-on-pay vote.
How much does Sutro Biopharma, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Sutro Biopharma, Inc reported total board compensation of $495,703 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| William Newell | $239,693 | $0 | $0 | $0 | $0 | $0 | $1,431,618 | $1,671,311 |
| Former Chief Executive Officer | ||||||||
| Jane Chung | 652,000 | 0 | 167,400 | 245,280 | 465,750 | 0 | 45,500 | 1,575,930 |
| Chief Executive Officer | ||||||||
| Hans-Peter Gerber | 527,532 | 0 | 61,425 | 110,127 | 243,818 | 0 | 0 | 942,902 |
| Chief Scientific Officer | ||||||||
| Gregory Chow | 277,083 | 25,000 | 88,000 | 245,938 | 218,500 | 0 | 0 | 854,522 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| William Newell | $1,671,311 | $2,332,343 | $2,129,979 | ↓ −661,032 |
| Jane Chung | 1,575,930 | 1,443,360 | — | ↑ +132,570 |
| Hans-Peter Gerber | 942,902 | 1,153,932 | 1,626,976 | ↓ −211,030 |
| Gregory Chow | 854,522 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our 2025 compensation strategy emphasizes pay for performance by using both performance-based annual cash incentives and long-term equity awards in the form of stock options and RSUs. Stock options are utilized because they only provide value if the stock price increases. RSUs are also used to retain talent, align with long-term value (both increases and reductions), and because RSUs are less dilutive than stock options.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gregory Chow | RSU | — | — | — | — | — | $88,000 |
| Jane Chung | Option | — | — | — | — | — | 245,280 |
| Jane Chung | RSU | — | — | — | — | — | 167,400 |
| Hans-Peter Gerber | Option | — | — | — | — | — | 110,127 |
| Gregory Chow | Option | — | — | — | — | — | 245,938 |
| Hans-Peter Gerber | RSU | — | — | — | — | — | 61,425 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gregory Chow | $88,000 | $0 | $245,938 | 0.0% |
| Jane Chung | 167,400 | 0 | 245,280 | 0.0% |
| Hans-Peter Gerber | 61,425 | 0 | 110,127 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jane Chung | Option | 126 | 27.5 | — |
| Jane Chung | Option | 263 | 81.7 | — |
| Jane Chung | RSU | 788 | — | 9,117 |
| Hans-Peter Gerber | Option | 1,003 | 10.38 | — |
| Jane Chung | Option | 1,253 | 45.4 | — |
| Jane Chung | Option | 1,254 | 57.9 | — |
| Jane Chung | RSU | 1,376 | — | 15,920 |
| Jane Chung | Option | 1,562 | 45.4 | — |
| Jane Chung | Option | 1,626 | 27.5 | — |
| Hans-Peter Gerber | RSU | 3,375 | — | 39,049 |
| Hans-Peter Gerber | Option | 3,375 | 45.4 | — |
| Jane Chung | RSU | 5,000 | — | 57,850 |
| Hans-Peter Gerber | Option | 6,922 | 10.38 | — |
| Jane Chung | RSU | 7,500 | — | 86,775 |
| Hans-Peter Gerber | RSU | 7,500 | — | 86,775 |
| Hans-Peter Gerber | Option | 7,657 | 37.7 | — |
| Gregory Chow | Option | 8,200 | 10.38 | — |
| Hans-Peter Gerber | Option | 9,954 | 5.4 | — |
| Gregory Chow | RSU | 10,000 | — | 115,700 |
| Hans-Peter Gerber | RSU | 11,375 | — | 131,609 |
| Jane Chung | Option | 20,247 | 5.4 | — |
| Gregory Chow | Option | 27,500 | 8.8 | — |
| Jane Chung | Option | 30,128 | 5.4 | — |
| Jane Chung | RSU | 31,000 | — | 358,670 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Connie MatsuiIndependent · Nominating/Governance | $80,000 | $0 | $41,795 | — | $0 | $121,795 |
| Joseph M. LobackiIndependent · Audit · Compensation (Chair) | 67,000 | 0 | 41,795 | — | 0 | 108,795 |
| Jon Wigginton, M.DIndependent · Science and Technology (Chair) · Compensation | 58,500 | 0 | 41,795 | — | 0 | 100,295 |
| Sukhi JagpalIndependent · Audit (Chair) | 57,500 | 0 | 41,795 | — | 0 | 99,295 |
| Heidi HunterIndependent · Science and Technology · Audit | 57,500 | 0 | 41,795 | — | 0 | 99,295 |
| James PanekIndependent · Nominating/Governance (Chair) · Science and Technology | 55,000 | 0 | 41,795 | — | 0 | 96,795 |
| Daniel H. PetreeIndependent · Compensation · Nominating/Governance | 53,500 | 0 | 41,795 | — | 0 | 95,295 |
| Michael Dybbs, Ph.DIndependent · Science and Technology | 45,000 | 0 | 41,795 | — | 0 | 86,795 |
| John Freund, M.DIndependent · Departed during FY | 21,703 | 0 | — | — | 0 | 21,703 |
| Jane Chung, R.PhEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $41,795 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 17,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $495,703 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $495,703 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sutro Biopharma as a peer
Companies that benchmark against STRO
3 companies name STRO as a compensation peer
- C4 Therapeutics, Inc.CCCCFY2025
- Nurix Therapeutics, Inc.NRIXFY2025
- Personalis, Inc.PSNLFY2025
- UroGen Pharma Ltd.URGNFY2025
- Zymeworks Inc.ZYMEFY2025
Each company listed discloses STRO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named STRO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MGNX MacroGenics, Inc.ALEC Alector, Inc.GOSS Gossamer Bio, Inc.NRIX Nurix Therapeutics, Inc.RCUS Arcus Biosciences, Inc.REPL Replimune Group, Inc.ATRA Atara Biotherapeutics, Inc.KURA Kura Oncology, Inc.CRBU Caribou Biosciences, Inc.ALLO Allogene Therapeutics, Inc.MRSN Mersana Therapeutics, Inc.ZYME Zymeworks Inc.PSTX Poseida Therapeutics, Inc.GTHX G1 Therapeutics, Inc.SGMO Sangamo Therapeutics, Inc.GRTS Gritstone Bio, Inc.IGMS IGM Biosciences, Inc.
Peer reciprocity
The companies Sutro Biopharma, Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | $775,000 | $2,199,450 | $6,008,860 | $658,750 | $9,656,813 |
| 2 | Zymeworks Inc. | 2025 | Kenneth Galbraith | 656,763 | 2,538,240 | 2,366,565 | 340,990 | 6,613,180 |
| 3 | Nurix Therapeutics, Inc. | 2025 | Arthur Sands | 674,584 | 0 | 5,166,196 | 510,000 | 6,374,138 |
| 4 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 5 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 6 | Kura Oncology, Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 7 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 8 | Gritstone Bio, Inc. | 2023 | Andrew Allen | 645,833 | 2,429,830 | 0 | 355,208 | 3,444,071 |
| 9 | G1 Therapeutics, Inc. | 2023 | John Bailey | 794,976 | 1,392,022 | 666,209 | 387,551 | 3,250,658 |
| 10 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 11 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 12 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 13 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 14 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 15 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 16 | Sutro Biopharma, Inc | 2025 | Jane Chung | 652,000 | 167,400 | 245,280 | 465,750 | 1,575,930 |
| 17 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
| — | Sangamo Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sutro Biopharma, Inc | 115% | Options 59 · RSU 41 | not disclosed | FW Cook |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| Caribou Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| G1 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, Aon’s Human Capital Solutions Practice |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Gritstone Bio, Inc. | not disclosed | RSU 100 | not disclosed | Aon |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Kura Oncology, Inc. | 150% | not disclosed | No | Alpine Rewards |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Mersana Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Nurix Therapeutics, Inc. | not disclosed | Option 60 · RSU 40 | not disclosed | Aon plc |
| Poseida Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Sangamo Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Zymeworks Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon plc (Talent Solutions practice) |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-05 | 11,329,946 | 22,412 | 6,452 | 99.8% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-05 | 99.8%a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Gregory Chow | CFO | 2026-06-02 | D | 2,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Gregory Chow | CFO | 2026-06-02 | A | 2,500 | 0 | 0 | Common | Form 4 ↗ |
| Connie Matsui | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Dybbs | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Heidi Hunter | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sukhi Jagpal | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph M. Lobacki | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Panek | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel H. Petree | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon Marc Wigginton | Director | 2026-06-05 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans-Peter Gerber | Chief Scientific Officer | 2026-09-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans-Peter Gerber | Chief Scientific Officer | 2026-09-18 | D | 1,345 | 15 | 20,632 | Common | Form 4 ↗ |
| Hans-Peter Gerber | Chief Scientific Officer | 2026-09-18 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (58 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, William Newell. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · page 36. As printed: 1,671,311. View filing ↗
- Section 01, Jane Chung. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 1,575,930. View filing ↗
- Section 01, Hans-Peter Gerber. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 942,902. View filing ↗
- Section 01, Gregory Chow. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table”. As printed: 854,522. View filing ↗
- Section 03, Gregory Chow RSU. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Jane Chung Option. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Jane Chung RSU. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Hans-Peter Gerber Option. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Gregory Chow Option. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 03, Hans-Peter Gerber RSU. DEF 14A, filed 2026-04-22. Section “EXECUTIVE COMPENSATION TABLES” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-23. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Connie Matsui. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 121,795. View filing ↗
- Section 08, Joseph M. Lobacki. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 108,795. View filing ↗
- Section 08, Jon Wigginton, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 100,295. View filing ↗
- Section 08, Sukhi Jagpal. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 99,295. View filing ↗
- Section 08, Heidi Hunter. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 99,295. View filing ↗
- Section 08, James Panek. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 96,795. View filing ↗
- Section 08, Daniel H. Petree. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 95,295. View filing ↗
- Section 08, Michael Dybbs, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 86,795. View filing ↗
- Section 08, John Freund, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 21,703. View filing ↗
- Section 08, Jane Chung, R.Ph. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Gregory Chow 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory Chow 2026-06-02. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Connie Matsui 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Dybbs 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heidi Hunter 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sukhi Jagpal 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph M. Lobacki 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Panek 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel H. Petree 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jon Marc Wigginton 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hans-Peter Gerber 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hans-Peter Gerber 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hans-Peter Gerber 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-08. Item 5.07 · say-on-pay result. As reported: 99.8%. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 495,703 + equity 0 + all other 0 = 495,703, summed across the director compensation table rows.
- Arcus Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. View filing ↗
- Zymeworks Inc., Section 10b CEO total. DEF 14A, filed 2026-10-26. CEO total compensation as printed in Zymeworks Inc.'s own proxy. As printed: 6,613,180. View filing ↗
- Nurix Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Nurix Therapeutics, Inc.'s own proxy. As printed: 6,374,138. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- Replimune Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. View filing ↗
- Kura Oncology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology, Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- Poseida Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. View filing ↗
- Gritstone Bio, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Gritstone Bio, Inc.'s own proxy. As printed: 3,444,071. View filing ↗
- G1 Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in G1 Therapeutics, Inc.'s own proxy. As printed: 3,250,658. View filing ↗
- IGM Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Caribou Biosciences, Inc., Section 10b CEO total. DEFR 14A, filed 2026-05-01. CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. View filing ↗
- Mersana Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗
- Sutro Biopharma, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sutro Biopharma, Inc's own proxy. As printed: 1,575,930. View filing ↗
- Atara Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗
- Section 10a, Nurix Therapeutics, Inc. reciprocity. DEF 14A. Nurix Therapeutics, Inc. names Sutro Biopharma, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Zymeworks Inc. reciprocity. DEF 14A. Zymeworks Inc. names Sutro Biopharma, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Gritstone Bio, Inc. reciprocity. DEF 14A. Gritstone Bio, Inc. names Sutro Biopharma, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗